Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Developing a Novel Biomarker for Response and Prognosis of HBV-related Hepatocellular Carcinoma Treated With Radiotherapy: Personalized Cell-free Virus-host Chimera DNA

NCT05752890 is registered in ClinicalTrials.gov with National Taiwan University Hospital as lead sponsor.

NCT NCT05752890
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05752890 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Developing a Novel Biomarker for Response and Prognosis of HBV-related Hepatocellular Carcinoma Treated With Radiotherapy: Personalized Cell-free Virus-host Chimera DNA
Lead sponsor
National Taiwan University Hospital
Phase
Observational
Overall status
Not yet recruiting
Start date
March 1, 2023
Completion date
January 31, 2031
Enrollment
95 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

biomarker, hepatitis b virus, hepatocellular carcinoma, radiotherapy